Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding round

After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay.